U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Actavis Laboratories FL, Inc. - 567857 - 09/01/2021
  1. Warning Letters


Actavis Laboratories FL, Inc. MARCS-CMS 567857 —

Delivery Method:
VIA Electronic Mail

Recipient Name
Kristopher J. Preisinger
Recipient Title
Site General Manager
Actavis Laboratories FL, Inc.

4955 Orange Dr.
Davie, FL 33314
United States

Issuing Office:
Dallas District Office

United States

Mr. Preisinger:

The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter # 567857 dated February 1, 2019. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

If you have questions regarding the contents of this letter, you may contact Jamillah Selby, Compliance Officer via phone at 214-253-5218 or email at jamillah.selby@fda.hhs.gov

John W. Diehl, M.S
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

Back to Top